Research Project
Clinical Study to Evaluate Immunogenicity and Safety of CERVAVAC vs Gardasil in Girls and Women
Principal Investigator
Dr Abhishek Agarwal
Funder
Serum Institute of India
Study Period
2024 - 2025
Study Sites
India, Shillong
Summary
Completed: This observer-blind clinical trial compared the immunogenicity of CERVAVAC with the established Gardasil vaccine. Conducted in Shillong, the study followed 2000 subjects across different age cohorts, providing critical safety and comparative data for the Indian-made qHPV vaccine.